Surviving breast cancer is a triumph, but the financial battle often continues long after treatment ends. A staggering number of survivors face a hidden crisis: mounting healthcare costs that can persist for years. A groundbreaking study from the University of Queensland sheds light on this often-overlooked struggle, revealing the surprising financial toll of surviving this disease.
Led by Dr. Aarushi Dhingra during her PhD at UQ, the research delves into the long-term financial repercussions of a breast cancer diagnosis. Dr. Dhingra highlights a stark reality: "While survival rates are thankfully rising, many survivors face a significant and lasting financial burden."
And this is the part most people miss: It's not just the initial treatment costs. The study, utilizing data from nearly 500 breast cancer survivors in the Australian Longitudinal Study of Women’s Health, found that out-of-pocket expenses for non-hospital services and prescription medication can be substantial. Even with Medicare, survivors face an average of $250 in the month of diagnosis and a staggering $2000 in the first year. That's roughly 5% of the average monthly income for Australian women, and even more for those working part-time.
"While these figures might seem modest at first glance, they don’t account for the potential loss of income during treatment," Dr. Dhingra explains. The financial strain begins even before diagnosis, with costs escalating a month prior and remaining high for the initial six months of treatment, depending on the required care and medications.
But here's where it gets controversial: The study points to a system where even with public healthcare, survivors are left shouldering a significant financial burden. The gap between Medicare rebates and provider fees, co-payments for medication, and the cost of essential allied health services like physiotherapy or psychology can create a constant financial pressure.
Health economist Professor Brenda Gannon emphasizes the study's importance: "This research fills a critical knowledge gap regarding the comprehensive financial impact of breast cancer on survivors. Understanding this impact is crucial, especially considering our aging population, the rise of age-related diseases, and the technological advancements driving higher survival rates."
The findings, published in the European Journal of Health Economics, could be a game-changer for policymakers. By identifying specific cost drivers, they can develop targeted interventions to alleviate the financial strain on survivors. The study was co-authored by Associate Professor Terence Cheng from Monash University, and UQ’s Professor Luke Connelly and Professor Gita Mishra. Dr. Dhingra now continues her research as a Fellow at the University of Bologna, Italy.
This study raises important questions: How can we ensure that the financial burden of survival doesn't overshadow the joy of beating cancer? Should healthcare systems be restructured to provide more comprehensive coverage for survivors? We invite you to share your thoughts and experiences in the comments below.
